Aurinia Pharmaceuticals (AUPH) Operating Margin (2019 - 2026)

Aurinia Pharmaceuticals has reported Operating Margin for 8 years, with the latest figure at 53.31% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin rose 1833.0% year-over-year to 53.31%; the trailing twelve-month figure through Mar 2026 stood at 41.73% (up 2944.0% YoY), and the FY2025 full-year result was 37.06%, up 3906.0% from the prior year.
• Operating Margin for Q1 2026 stood at 53.31%, up from 43.1% in the prior quarter.
• The five-year high for Operating Margin was 53.31% in Q1 2026, with the low at 175.18% in Q1 2022.
• Historically, Operating Margin has averaged 26.66% across 5 years, with a median of 17.03% in 2022.
• Annual changes were most pronounced in 2022 — Operating Margin soared 535469 bps — and 2023, when it tumbled 1280 bps.
• Aurinia Pharmaceuticals' Operating Margin stood at 98.82% in 2022, then surged by 33 bps to 65.8% in 2023, then surged by 96 bps to 2.79% in 2024, then soared by 1646 bps to 43.1% in 2025, then gained by 24 bps to 53.31% in 2026.
• The last three Operating Margin figures came in at 53.31% (Q1 2026), 43.1% (Q4 2025), and 40.49% (Q3 2025), per Business Quant data.